Warning: The NCBI web site requires JavaScript to function. more...
A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis.
Le Goff B, Soltner E, Charrier C, Maugars Y, Rédini F, Heymann D, Berthelot JM.
Arthritis Res Ther. 2009;11(6):R185. Epub 2009 Dec 10.
Related citations
Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis.
Sims NA, Green JR, Glatt M, Schlict S, Martin TJ, Gillespie MT, Romas E.
Arthritis Rheum. 2004 Jul;50(7):2338-46.
Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis.
Herrak P, Görtz B, Hayer S, Redlich K, Reiter E, Gasser J, Bergmeister H, Kollias G, Smolen JS, Schett G.
Arthritis Rheum. 2004 Jul;50(7):2327-37.
Artemether: a new therapeutic strategy in experimental rheumatoid arthritis.
Cuzzocrea S, Saadat F, Di Paola R, Mirshafiey A.
Immunopharmacol Immunotoxicol. 2005;27(4):615-30.
Application of surface roughness analysis on micro-computed tomographic images of bone erosion: examples using a rodent model of rheumatoid arthritis.
Silva MD, Ruan J, Siebert E, Savinainen A, Jaffee B, Schopf L, Chandra S.
Mol Imaging. 2006 Oct-Dec;5(4):475-84.
Therapeutic efficacy of experimental rheumatoid arthritis with low-dose methotrexate by increasing partially CD4+CD25+ Treg cells and inducing Th1 to Th2 shift in both cells and cytokines.
Xinqiang S, Fei L, Nan L, Yuan L, Fang Y, Hong X, Lixin T, Juan L, Xiao Z, Yuying S, Yongzhi X.
Biomed Pharmacother. 2010 Sep;64(7):463-71. Epub 2010 Feb 25.
Adenosine abolishes MTX-induced suppression of osteoclastogenesis and inflammatory bone destruction in adjuvant-induced arthritis.
Teramachi J, Kukita A, Li YJ, Ushijima Y, Ohkuma H, Wada N, Watanabe T, Nakamura S, Kukita T.
Lab Invest. 2011 May;91(5):719-31. Epub 2011 Feb 21.
Effect of minodronic acid (ONO-5920) on bone mineral density and arthritis in adult rats with collagen-induced arthritis.
Yamane I, Hagino H, Okano T, Enokida M, Yamasaki D, Teshima R.
Arthritis Rheum. 2003 Jun;48(6):1732-41.
Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA, Lubberts E, Helsen MM, Saxne T, Coenen-de Roo CJ, Heinegård D, van den Berg WB.
Arthritis Res. 1999;1(1):81-91. Epub 1999 Oct 26.
The effect of low dose methotrexate on bone density.
Cranney AB, McKendry RJ, Wells GA, Ooi DS, Kanigsberg ND, Kraag GR, Smith CD.
J Rheumatol. 2001 Nov;28(11):2395-9.
Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis.
Lange F, Bajtner E, Rintisch C, Nandakumar KS, Sack U, Holmdahl R.
Ann Rheum Dis. 2005 Apr;64(4):599-605. Epub 2004 Sep 2.
Effects of interleukin 1 receptor antagonist alone and in combination with methotrexate in adjuvant arthritic rats.
Bendele A, Sennello G, McAbee T, Frazier J, Chlipala E, Rich B.
J Rheumatol. 1999 Jun;26(6):1225-9.
Age-depending effects of methotrexate treatment on systemic bone turnover in experimental adjuvant arthritis.
Segawa Y, Tsuzuike N, Itokazu Y, Omata T, Inoue N, Aota S, Okazaki Y, Nakamura T.
Arzneimittelforschung. 1999 Jan;49(1):38-43.
Addition of bisphosphonate to antibiotic and anti-inflammatory treatment reduces bone resorption in experimental Staphylococcus aureus-induced arthritis.
Verdrengh M, Carlsten H, Ohlsson C, Tarkowski A.
J Orthop Res. 2007 Mar;25(3):304-10.
[Secondary osteoporosis. Bisphosphonates as a possible strategy for the prevention of bone destruction in rheumatoid arthritis].
Suzuki Y.
Clin Calcium. 2007 Dec;17(12):1909-13. Review. Japanese.
Treatment of experimental adjuvant arthritis with the combination of methotrexate and lyophilized Enterococcus faecium enriched with organic selenium.
Rovenský J, Svík K, Stancíková M, Istok R, Ebringer L, Ferencík M.
Folia Microbiol (Praha). 2002;47(5):573-8.
Synergistic interaction between methotrexate and a superoxide dismutase mimetic: pharmacologic and potential clinical significance.
Cuzzocrea S, Mazzon E, di Paola R, Genovese T, Muià C, Caputi AP, Salvemini D.
Arthritis Rheum. 2005 Dec;52(12):3755-60.
RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies.
Stolina M, Schett G, Dwyer D, Vonderfecht S, Middleton S, Duryea D, Pacheco E, Van G, Bolon B, Feige U, Zack D, Kostenuik P.
Arthritis Res Ther. 2009;11(6):R187. Epub 2009 Dec 11.
Inhibition of osteoclasts prevents cartilage loss and pain in a rat model of degenerative joint disease.
Strassle BW, Mark L, Leventhal L, Piesla MJ, Jian Li X, Kennedy JD, Glasson SS, Whiteside GT.
Osteoarthritis Cartilage. 2010 Oct;18(10):1319-28. Epub 2010 Jul 13.
Effect of zoledronic acid on incorporation of a bioceramic bone graft substitute.
Välimäki VV, Moritz N, Yrjans JJ, Vuorio E, Aro HT.
Bone. 2006 Mar;38(3):432-43. Epub 2005 Dec 9.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on